Empagliflozin alleviates diabetic cardiomyopathy via inhibiting excessive autophagy and adverse remodeling in type 1 diabetic mice

28 August 2022 (13:15 - 14:00)
Organised by:
Congress Presentation Part of: Cellular effectiveness of drug therapies Cardiomyopathies ESC Professional Premium Access ESC Congress 2022